MLH1 and colorectal cancer: Together, these features suggest that combining metabolic intervention (e.g., glycolysis or mitochondrial inhibitors) with immunotherapy may provide synergistic benefits in MLH1-deficient Lynch syndrome-associated colorectal cancer and deserve further pre-clinical and clinical exploration.